In recent months, we have seen encouraging signs of a new commitment to the social contract drug makers have with patients. Novo Nordisk and Allergan have made pledges to hold the line on drug prices. Mylan has taken responsibility for the price increases for EpiPen, and is promising to do more to advance affordability. More recently, Regeneron engaged early on in a meaningful and responsible way to discuss pricing of a new therapy.
At Express Scripts, we fully recognize there is no silver bullet to solving the problem of high drug prices. However, these discussions and concrete actions by some drug makers are a strong start, and we hope they are the first of many more to come.